Looking back at the UPC’s ‘successful’ first year

Court seen as “exceeding expectations” | Experts urge caution, emphasising that confident and reliable court judgments are needed | High-stakes patent litigation, especially in pharmaceuticals, remains predominantly within national courts.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Arnold & Porter loses another regulatory partner to growing rival

7 January 2026 A Brussels-based partner, specialising in pharmaceuticals and biologics, jumps ship as a competitor firm continues to build out its EU healthcare regulatory bench.

Americas

Merchant & Gould hires 13 attorneys to open new Boston office

6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

More features

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Bird & Bird targets Nordic life sciences growth with regulatory hire

PTAB year in review: A shifting landscape and outlook for 2026

UPC: A review of 2025 and what to expect in 2026

Looking back at the UPC’s ‘successful’ first year

More on this story

Editor's picks

Editor's picks

More features